News

The novel anti-IL-6 monoclonal antibody RYI-008 is believed to have a potential to define new paradigm in the treatment of autoimmune diseases and cancer. RuiYi president and CEO

Paradigm 2 is a multi-centre, blinded study designed to assess the safety and efficacy of the glycopegylated recombinant factor IX as on-demand or prophylactic treatment against haemophilia B.

The app enables to share large data sets in Illumina’s BaseSpace cloud, where they can easily be reviewed and included in Elsevier’s open access journal, Genomics Data. The

As per the terms of the agreement, BASF will use Dyadic’s patented and proprietary C1 platform technology to develop, manufacture, distribute and sell industrial enzymes in certain fields

As per the extension agreement, Galapagos will fund and complete a Phase 2 program in Crohn’s disease, which is designed to facilitate rapid progression into Phase 3. AbbVie

Neucardin is a genetically engineered recombinant peptide fragment of neuregulin-1 that is used as a therapeutic drug to treat advanced chronic heart failure (CHF). As per the terms

DCVax-L mobilizes a cancer patient’s whole immune system to attack the full set of biomarker targets on the tumour. King’s College Hospital neuro-oncology lead and consultant neurosurgeon Dr.

Almac and the departments of Biochemical Engineering and Chemistry at UCL are set to complete the R&D work with high level input from professors John Ward and Helen

The safety and tolerability profile of single ascending doses of TTI-1612 will be assessed in the study. Stem Cell Therapeutics chief scientific officer Dr. Bob Uger said, "We